These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23790597)

  • 1. Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke.
    Ahmad Y; Lip GY; Lane DA
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S4-S13. PubMed ID: 23790597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silent atrial fibrillation as a stroke risk factor and anticoagulation indication.
    Glotzer TV; Ziegler PD
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S14-23. PubMed ID: 23790594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The assessment of stroke and bleeding risk in atrial fibrillation: where are we now?
    Pamukcu B; Lane DA; Lip GY
    Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1703-10. PubMed ID: 21108552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.
    Salim I; Al Suwaidi J; Ghadban W; Salam AM
    Expert Opin Drug Saf; 2013 Jan; 12(1):53-63. PubMed ID: 23095103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients.
    Wilke T; Groth A; Mueller S; Pfannkuche M; Verheyen F; Linder R; Maywald U; Kohlmann T; Feng YS; Breithardt G; Bauersachs R
    Thromb Haemost; 2012 Jun; 107(6):1053-65. PubMed ID: 22398417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulants, renal failure and atrial fibrillation.
    Genovesi S; Santoro A
    Expert Opin Drug Saf; 2013 Jan; 12(1):1-3. PubMed ID: 23163428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anticoagulation in atrial fibrillation].
    Binggeli C; Brunckhorst CB
    Herz; 2008 Feb; 33(1):13-9. PubMed ID: 18273573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Atrial fibrillation and thromboembolic events prevention. State of the art].
    Matteoli S; Trappolini M; Chillotti FM
    Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke prevention in atrial fibrillation.
    Mohammed I; Mohmand-Borkowski A; Burke JF; Kowey PR
    J Cardiovasc Med (Hagerstown); 2012 Feb; 13(2):73-85. PubMed ID: 22193836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
    Savelieva I; Bajpai A; Camm AJ
    Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C; Barrios V; Jimenez D
    Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation for atrial fibrillation: epidemiology informing a difficult clinical decision.
    Singer DE
    Proc Assoc Am Physicians; 1996 Jan; 108(1):29-36. PubMed ID: 8834062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Pisters R; Nieuwlaat R; Lane DA; Crijns HJ; Lip GY
    Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anticoagulation in atrial fibrillation. Strategies in special situations].
    Volkmann H; Walter M; Walter C; Vetter S
    Clin Res Cardiol Suppl; 2011 May; 6():58-65. PubMed ID: 22528179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroke prevention in atrial fibrillation patients.
    Marinigh R; Lip GY; Lane DA
    Expert Opin Pharmacother; 2010 Oct; 11(14):2331-50. PubMed ID: 20718589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
    Lenchus JD
    Hosp Pract (1995); 2013 Feb; 41(1):49-60. PubMed ID: 23466967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left atrial appendage closure devices. Their role in 2013.
    Mangner N; Sandri M; Lurz P; Dähnert I; Schuler G; Möbius-Winkler S
    Minerva Cardioangiol; 2013 Apr; 61(2):125-34. PubMed ID: 23492596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.